口服乳香（Pistacia lentiscus）对炎症性肠病患者的血浆游离氨基酸谱的影响：一项随机临床试验。

Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial.

机构信息

Department of Dietetics and Nutritional Science, School of Health Science and Education, Harokopio University, Athens, Greece.

Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.

出版信息

Phytomedicine. 2019 Mar 15;56:40-47. doi: 10.1016/j.phymed.2018.08.008. Epub 2018 Aug 13.

DOI:10.1016/j.phymed.2018.08.008

PMID:30668352

Abstract

BACKGROUND

Natural products have been studied regarding their effectiveness on Inflammatory Bowel Disease (IBD).

HYPOTHESIS/PURPOSE: To examine the effects of Mastiha (Pistacia lentiscus var. Chia) on clinical course and amino acid (AA) profile of patients in remission.

STUDY DESIGN

This is a randomised, double-blind, placebo-controlled clinical trial.

METHODS

Patients (n = 68) were randomly allocated to Mastiha (2.8  g/day) or placebo adjunct to stable medication. Free AAs were identified applying Gas Chromatography-Mass Spectrometry in plasma. Medical-dietary history, Inflammatory Bowel Disease Questionnaire, Harvey-Bradshaw Index, Partial Mayo Score, biochemical, faecal and blood inflammatory markers were assessed. Primary endpoint was the clinical relapse rate at 6 months. Secondary endpoints included variations in free AAs, inflammatory biomarkers and quality of life. Statistical significance was set at 0.05.

RESULTS

Concerning AAs and biochemical data, alanine (p = 0.006), valine (p = 0.047), proline (p = 0.022), glutamine (p < 0.001) and tyrosine (p = 0.043) along with total cholesterol (p = 0.032) and LDL cholesterol (p = 0.045) increased only in placebo group compared with baseline and the change between the study groups was significantly different. Inflammatory markers had not a significantly different change between the two groups, even serum IL-6, faecal calprotectin and faecal lactoferrin increased only in the placebo group. Although Mastiha was not proven superior to placebo in remission rate (17.6% vs. 23.5%, p = 0.549), attenuation in increase of free AAs levels in verum group is reported.

CONCLUSION

Mastiha inhibited an increase in plasma free AAs seen in patients with quiescent IBD. Since change of AAs is considered an early prognostic marker of disease activity, this indicates a potential role of Mastiha in remission maintenance.

摘要

背景

天然产物因其对炎症性肠病（IBD）的疗效而受到研究。

假设/目的：检查乳香（Pistacia lentiscus var. Chia）对缓解期患者临床病程和氨基酸（AA）谱的影响。

研究设计

这是一项随机、双盲、安慰剂对照的临床试验。

方法

将患者（n=68）随机分配至乳香（2.8 g/天）或安慰剂联合稳定药物。应用气相色谱-质谱法在血浆中鉴定游离氨基酸。评估了医疗-饮食史、炎症性肠病问卷、Harvey-Bradshaw 指数、部分 Mayo 评分、生化、粪便和血液炎症标志物。主要终点是 6 个月时的临床复发率。次要终点包括游离氨基酸、炎症生物标志物和生活质量的变化。统计学意义设定为 0.05。

结果

就氨基酸和生化数据而言，与安慰剂组相比，仅在安慰剂组中，丙氨酸（p=0.006）、缬氨酸（p=0.047）、脯氨酸（p=0.022）、谷氨酰胺（p<0.001）和酪氨酸（p=0.043）以及总胆固醇（p=0.032）和 LDL 胆固醇（p=0.045）升高，并且研究组之间的变化明显不同。两组之间的炎症标志物变化没有显著差异，即使血清 IL-6、粪便钙卫蛋白和粪便乳铁蛋白仅在安慰剂组中增加。尽管乳香在缓解率方面并未优于安慰剂（17.6%比 23.5%，p=0.549），但在真药组中观察到游离 AA 水平升高的抑制。